Welcome to DrugBank 4.0! If you prefer, you can still go back to version 3.0.
Identification
NameCabergoline
Accession NumberDB00248  (APRD00836)
Typesmall molecule
Groupsapproved
Description

Cabergoline, an ergot derivative, is a long-acting dopamine agonist and prolactin inhibitor. It is used to treat hyperprolactinemic disorders and Parkinsonian Syndrome. Cabergoline possesses potent agonist activity on dopamine D2 receptors.

Structure
Thumb
Synonyms
SynonymLanguageCode
CabergolinaSpanishINN
CabergolinumLatinINN
SaltsNot Available
Brand names
NameCompany
CabaserPfizer
DostinexPfizer
Brand mixturesNot Available
Categories
CAS number81409-90-7
WeightAverage: 451.6043
Monoisotopic: 451.294725453
Chemical FormulaC26H37N5O2
InChI KeyInChIKey=KORNTPPJEAJQIU-KJXAQDMKSA-N
InChI
InChI=1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1
IUPAC Name
1-[3-(dimethylamino)propyl]-3-ethyl-1-{[(2R,4R,7R)-6-(prop-2-en-1-yl)-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),9,12,14-tetraen-4-yl]carbonyl}urea
SMILES
[H][C@@]12CC3=CNC4=CC=CC(=C34)[C@@]1([H])C[C@H](CN2CC=C)C(=O)N(CCCN(C)C)C(=O)NCC
Mass SpecNot Available
Taxonomy
KingdomOrganic Compounds
SuperclassHeterocyclic Compounds
ClassQuinolines and Derivatives
SubclassIndoloquinolines
Direct parentIndoloquinolines
Alternative parentsBenzoquinolines; Quinoline Carboxamides; Pyrroloquinolines; N-substituted Nicotinamides; Indoles; Isoindoles and Derivatives; Piperidinecarboxylic Acids; Ureides; Benzene and Substituted Derivatives; N-substituted Carboxylic Acid Imides; Pyrroles; Tertiary Carboxylic Acid Amides; Tertiary Amines; Polyamines; Carboxylic Acids; Enolates; Ergoline Derivatives
Substituentsbenzoquinoline; quinoline-3-carboxamide; pyrroloquinoline; n-substituted nicotinamide; indole or derivative; piperidinecarboxylic acid; indole; isoindole or derivative; ureide; carboxylic acid imide, n-substituted; piperidine; benzene; pyrrole; tertiary carboxylic acid amide; tertiary amine; carboxamide group; polyamine; carboxylic acid; enolate; carboxylic acid derivative; organonitrogen compound; amine
Classification descriptionThis compound belongs to the indoloquinolines. These are polycyclic aromatic compounds containing an indole fused to a quinoline.
Pharmacology
IndicationFor the treatment of hyperprolactinemic disorders, either idiopathic or due to prolactinoma (prolactin-secreting adenomas). May also be used to manage symptoms of Parkinsonian Syndrome as monotherapy during initial symptomatic management or as an adjunct to levodopa therapy during advanced stages of disease.
PharmacodynamicsCabergoline stimulates centrally-located dopaminergic receptors resulting in a number of pharmacologic effects. Five dopamine receptor types from two dopaminergic subfamilies have been identified. The dopaminergic D1 receptor subfamily consists of D1 and D5 subreceptors, which are associated with dyskinesias. The dopaminergic D2 receptor subfamily consists of D2, D3 and D4 subreceptors, which are associated with improvement of symptoms of movement disorders. Thus, agonist activity specific for D2 subfamily receptors, primarily D2 and D3 receptor subtypes, are the primary targets of dopaminergic antiparkinsonian agents. It is thought that postsynaptic D2 stimulation is primarily responsible for the antiparkinsonian effect of dopamine agonists, while presynaptic D2 stimulation confers neuroprotective effects. This semisynthetic ergot derivative exhibits potent agonist activity on dopamine D2- and D3-receptors. It also exhibits: agonist activity (in order of decreasing binding affinities) on 5-hydroxytryptamine (5-HT)2B, 5-HT2A, 5-HT1D, dopamine D4, 5-HT1A, dopamine D1, 5-HT1B and 5-HT2C receptors and antagonist activity on α2B, α2A, and α2C receptors. Parkinsonian Syndrome manifests when approximately 80% of dopaminergic activity in the nigrostriatal pathway of the brain is lost. As this striatum is involved in modulating the intensity of coordinated muscle activity (e.g. movement, balance, walking), loss of activity may result in dystonia (acute muscle contraction), Parkinsonism (including symptoms of bradykinesia, tremor, rigidity, and flattened affect), akathesia (inner restlessness), tardive dyskinesia (involuntary muscle movements usually associated with long-term loss of dopaminergic activity), and neuroleptic malignant syndrome, which manifests when complete blockage of nigrostriatal dopamine occurs. High dopaminergic activity in the mesolimbic pathway of the brain causes hallucinations and delusions; these side effects of dopamine agonists are manifestations seen in patients with schizophrenia who have overractivity in this area of the brain. The hallucinogenic side effects of dopamine agonists may also be due to 5-HT2A agonism. The tuberoinfundibular pathway of the brain originates in the hypothalamus and terminates in the pituitary gland. In this pathway, dopamine inhibits lactotrophs in anterior pituitary from secreting prolactin. Increased dopaminergic activity in the tuberoinfundibular pathway inhibits prolactin secretion.
Mechanism of actionThe dopamine D2 receptor is a 7-transmembrane G-protein coupled receptor associated with Gi proteins. In lactotrophs, stimulation of dopamine D2 causes inhibition of adenylyl cyclase, which decreases intracellular cAMP concentrations and blocks IP3-dependent release of Ca2+ from intracellular stores. Decreases in intracellular calcium levels may also be brought about via inhibition of calcium influx through voltage-gated calcium channels, rather than via inhibition of adenylyl cyclase. Additionally, receptor activation blocks phosphorylation of p42/p44 MAPK and decreases MAPK/ERK kinase phosphorylation. Inhibition of MAPK appears to be mediated by c-Raf and B-Raf-dependent inhibition of MAPK/ERK kinase. Dopamine-stimulated growth hormone release from the pituitary gland is mediated by a decrease in intracellular calcium influx through voltage-gated calcium channels rather than via adenylyl cyclase inhibition. Stimulation of dopamine D2 receptors in the nigrostriatal pathway leads to improvements in coordinated muscle activity in those with movement disorders. Cabergoline is a long-acting dopamine receptor agonist with a high affinity for D2 receptors. Receptor-binding studies indicate that cabergoline has low affinity for dopamine D1, α1,- and α2- adrenergic, and 5-HT1- and 5-HT2-serotonin receptors.
AbsorptionFirst-pass effect is seen, however the absolute bioavailability is unknown.
Volume of distributionNot Available
Protein bindingModerately bound (40% to 42%) to human plasma proteins in a concentration-independent manner.
Metabolism

Hepatic. Cabergoline is extensively metabolized, predominately via hydrolysis of the acylurea bond of the urea moiety. Cytochrome P-450 mediated metabolism appears to be minimal. The main metabolite identified in urine is 6-allyl-8b-carboxy-ergoline (4-6% of dose). Three other metabolites were identified urine (less than 3% of dose).

SubstrateEnzymesProduct
Cabergoline
    6-allyl-8b-carboxy-ergolineDetails
    Route of eliminationAfter oral dosing of radioactive cabergoline to five healthy volunteers, approximately 22% and 60% of the dose was excreted within 20 days in the urine and feces, respectively. Less than 4% of the dose was excreted unchanged in the urine.
    Half lifeThe elimination half-life is estimated from urinary data of 12 healthy subjects to range between 63 to 69 hours.
    Clearance
    • renal cl=0,008 L/min
    • nonrenal cl=3.2 L/min
    ToxicityOverdosage might be expected to produce nasal congestion, syncope, or hallucinations.
    Affected organisms
    • Humans and other mammals
    PathwaysNot Available
    SNP Mediated EffectsNot Available
    SNP Mediated Adverse Drug ReactionsNot Available
    ADMET
    Predicted ADMET features
    Property Value Probability
    Human Intestinal Absorption + 1.0
    Blood Brain Barrier + 0.9383
    Caco-2 permeable - 0.6583
    P-glycoprotein substrate Substrate 0.7972
    P-glycoprotein inhibitor I Inhibitor 0.8903
    P-glycoprotein inhibitor II Inhibitor 0.7698
    Renal organic cation transporter Non-inhibitor 0.5339
    CYP450 2C9 substrate Non-substrate 0.812
    CYP450 2D6 substrate Non-substrate 0.7438
    CYP450 3A4 substrate Substrate 0.6336
    CYP450 1A2 substrate Non-inhibitor 0.7733
    CYP450 2C9 substrate Non-inhibitor 0.7396
    CYP450 2D6 substrate Non-inhibitor 0.7124
    CYP450 2C19 substrate Non-inhibitor 0.8341
    CYP450 3A4 substrate Non-inhibitor 0.6476
    CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.8712
    Ames test Non AMES toxic 0.5619
    Carcinogenicity Non-carcinogens 0.8542
    Biodegradation Not ready biodegradable 0.846
    Rat acute toxicity 2.8786 LD50, mol/kg Not applicable
    hERG inhibition (predictor I) Weak inhibitor 0.6224
    hERG inhibition (predictor II) Non-inhibitor 0.5309
    Pharmacoeconomics
    Manufacturers
    • Impax laboratories inc
    • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
    • Par pharmaceutical inc
    • Watson laboratories inc
    • Pharmacia and upjohn co
    Packagers
    Dosage forms
    FormRouteStrength
    TabletOral0.5 mg
    Prices
    Unit descriptionCostUnit
    Cabergoline 0.5 mg tablet37.39USDtablet
    DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
    PatentsNot Available
    Properties
    Statesolid
    Experimental Properties
    PropertyValueSource
    melting point102-104 °CNot Available
    water solubilityInsolubleNot Available
    logP2.6Not Available
    Predicted Properties
    PropertyValueSource
    water solubility6.40e-02 g/lALOGPS
    logP2.97ALOGPS
    logP2.58ChemAxon
    logS-3.9ALOGPS
    pKa (strongest acidic)15.25ChemAxon
    pKa (strongest basic)9.32ChemAxon
    physiological charge2ChemAxon
    hydrogen acceptor count4ChemAxon
    hydrogen donor count2ChemAxon
    polar surface area71.68ChemAxon
    rotatable bond count8ChemAxon
    refractivity133.5ChemAxon
    polarizability52.5ChemAxon
    number of rings4ChemAxon
    bioavailability1ChemAxon
    rule of fiveYesChemAxon
    Ghose filterNoChemAxon
    Veber's ruleNoChemAxon
    MDDR-like ruleYesChemAxon
    Spectra
    SpectraNot Available
    References
    Synthesis Reference

    DrugSyn.org

    US4526892
    General Reference
    1. Pastor P, Tolosa E: [Cabergoline in the treatment of Parkinson’s disease] Neurologia. 2003 May;18(4):202-9. Pubmed
    2. Curran MP, Perry CM: Cabergoline : a review of its use in the treatment of Parkinson’s disease. Drugs. 2004;64(18):2125-41. Pubmed
    3. Bracco F, Battaglia A, Chouza C, Dupont E, Gershanik O, Marti Masso JF, Montastruc JL: The long-acting dopamine receptor agonist cabergoline in early Parkinson’s disease: final results of a 5-year, double-blind, levodopa-controlled study. CNS Drugs. 2004;18(11):733-46. Pubmed
    4. Miyagi M, Arai N, Taya F, Itoh F, Komatsu Y, Kojima M, Isaji M: Effect of cabergoline, a long-acting dopamine D2 agonist, on reserpine-treated rodents. Biol Pharm Bull. 1996 Nov;19(11):1499-502. Pubmed
    External Links
    ResourceLink
    KEGG DrugD00987
    KEGG CompoundC08187
    PubChem Compound54746
    PubChem Substance46508571
    ChemSpider49452
    ChEBI3286
    ChEMBLCHEMBL1201087
    Therapeutic Targets DatabaseDAP000251
    PharmGKBPA448708
    IUPHAR37
    Guide to Pharmacology37
    Drug Product Database2242471
    RxListhttp://www.rxlist.com/cgi/generic/cabergoline.htm
    Drugs.comhttp://www.drugs.com/cdi/cabergoline.html
    WikipediaCabergoline
    ATC CodesG02CB03N04BC06
    AHFS Codes
    • 28:36.20.04
    PDB EntriesNot Available
    FDA labelNot Available
    MSDSNot Available
    Interactions
    Drug Interactions
    Drug
    ErythromycinErythromycin increases serum levels and toxicity of cabergoline
    TramadolIncreased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
    TranylcypromineIncreased risk of serotonin syndrome. Use caution during concomitant therapy and monitor for symptoms of serotonin syndrome.
    TrazodoneIncreased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
    TrimipramineIncreased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
    VenlafaxineIncreased risk of serotonin syndrome. Monitor for symptoms of serotonin syndrome.
    VoriconazoleVoriconazole may increase the serum concentration of cabergoline likely by decreasing its metabolism. Concomitant therapy is contraindicated.
    ZolmitriptanConcomitant use of the serotonin 5-HT1D receptor agonist, zolmitriptan, and the ergot derivative, carbergoline, may result in additive vasoconstrictive effects. Concomitant use within 24 hours is contraindicated. Use of two serotonin modulators, such as zolmitriptan and carbergoline, increases the risk of serotonin syndrome. Consider alternate therapy or monitor for serotonin syndrome during concomitant therapy.
    Food Interactions
    • Absorption is not affected by food.
    • Take with food to improve tolerance.

    1. D(2) dopamine receptor

    Kind: protein

    Organism: Human

    Pharmacological action: yes

    Actions: agonist

    Components

    Name UniProt ID Details
    D(2) dopamine receptor P14416 Details

    References:

    1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. Pubmed
    2. Lombardi G, Varsaldi F, Miglio G, Papini MG, Battaglia A, Canonico PL: Cabergoline prevents necrotic neuronal death in an in vitro model of oxidative stress. Eur J Pharmacol. 2002 Dec 20;457(2-3):95-8. Pubmed
    3. Kageyama K, Nigawara T, Kamata Y, Takahashi T, Anzai J, Suzuki S, Osamura YR, Suda T: A case of macroprolactinoma with subclinical growth hormone production. Endocr J. 2002 Feb;49(1):41-7. Pubmed
    4. Pastor P, Tolosa E: [Cabergoline in the treatment of Parkinson’s disease] Neurologia. 2003 May;18(4):202-9. Pubmed
    5. Curran MP, Perry CM: Cabergoline : a review of its use in the treatment of Parkinson’s disease. Drugs. 2004;64(18):2125-41. Pubmed
    6. Miyagi M, Arai N, Taya F, Itoh F, Komatsu Y, Kojima M, Isaji M: Effect of cabergoline, a long-acting dopamine D2 agonist, on reserpine-treated rodents. Biol Pharm Bull. 1996 Nov;19(11):1499-502. Pubmed
    7. Ichikawa K, Kojima M: [Pharmacological effects of cabergoline against parkinsonism] Nippon Yakurigaku Zasshi. 2001 Jun;117(6):395-400. Pubmed
    8. Linazasoro G: Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease. Clin Neuropharmacol. 2008 Jan-Feb;31(1):19-24. Pubmed

    2. 5-hydroxytryptamine receptor 2B

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Actions: agonist

    Components

    Name UniProt ID Details
    5-hydroxytryptamine receptor 2B P41595 Details

    References:

    1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. Pubmed
    2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. Pubmed
    3. Sharif NA: Serotonin-2 receptor agonists as novel ocular hypotensive agents and their cellular and molecular mechanisms of action. Curr Drug Targets. 2010 Aug;11(8):978-93. Pubmed
    4. Sharif NA, McLaughlin MA, Kelly CR, Katoli P, Drace C, Husain S, Crosson C, Toris C, Zhan GL, Camras C: Cabergoline: Pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in the Cynomolgus monkey eyes. Exp Eye Res. 2009 Mar;88(3):386-97. Epub 2008 Nov 1. Pubmed
    5. Huang XP, Setola V, Yadav PN, Allen JA, Rogan SC, Hanson BJ, Revankar C, Robers M, Doucette C, Roth BL: Parallel functional activity profiling reveals valvulopathogens are potent 5-hydroxytryptamine(2B) receptor agonists: implications for drug safety assessment. Mol Pharmacol. 2009 Oct;76(4):710-22. Epub 2009 Jul 1. Pubmed

    3. D(3) dopamine receptor

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Actions: agonist

    Components

    Name UniProt ID Details
    D(3) dopamine receptor P35462 Details

    References:

    1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. Pubmed
    2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. Pubmed
    3. Sharif NA, McLaughlin MA, Kelly CR, Katoli P, Drace C, Husain S, Crosson C, Toris C, Zhan GL, Camras C: Cabergoline: Pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in the Cynomolgus monkey eyes. Exp Eye Res. 2009 Mar;88(3):386-97. Epub 2008 Nov 1. Pubmed

    4. 5-hydroxytryptamine receptor 2A

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Actions: agonist

    Components

    Name UniProt ID Details
    5-hydroxytryptamine receptor 2A P28223 Details

    References:

    1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. Pubmed
    2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. Pubmed
    3. Sharif NA: Serotonin-2 receptor agonists as novel ocular hypotensive agents and their cellular and molecular mechanisms of action. Curr Drug Targets. 2010 Aug;11(8):978-93. Pubmed
    4. Sharif NA, McLaughlin MA, Kelly CR, Katoli P, Drace C, Husain S, Crosson C, Toris C, Zhan GL, Camras C: Cabergoline: Pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in the Cynomolgus monkey eyes. Exp Eye Res. 2009 Mar;88(3):386-97. Epub 2008 Nov 1. Pubmed

    5. Alpha-2B adrenergic receptor

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Actions: antagonist

    Components

    Name UniProt ID Details
    Alpha-2B adrenergic receptor P18089 Details

    References:

    1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. Pubmed
    2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. Pubmed
    3. Sharif NA, McLaughlin MA, Kelly CR, Katoli P, Drace C, Husain S, Crosson C, Toris C, Zhan GL, Camras C: Cabergoline: Pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in the Cynomolgus monkey eyes. Exp Eye Res. 2009 Mar;88(3):386-97. Epub 2008 Nov 1. Pubmed
    4. Newman-Tancredi A, Cussac D, Audinot V, Nicolas JP, De Ceuninck F, Boutin JA, Millan MJ: Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor. J Pharmacol Exp Ther. 2002 Nov;303(2):805-14. Pubmed

    6. 5-hydroxytryptamine receptor 1D

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Actions: agonist

    Components

    Name UniProt ID Details
    5-hydroxytryptamine receptor 1D P28221 Details

    References:

    1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. Pubmed
    2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. Pubmed

    7. D(4) dopamine receptor

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Actions: agonist

    Components

    Name UniProt ID Details
    D(4) dopamine receptor P21917 Details

    References:

    1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. Pubmed
    2. Newman-Tancredi A, Cussac D, Audinot V, Nicolas JP, De Ceuninck F, Boutin JA, Millan MJ: Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor. J Pharmacol Exp Ther. 2002 Nov;303(2):805-14. Pubmed

    8. Alpha-2A adrenergic receptor

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Actions: antagonist

    Components

    Name UniProt ID Details
    Alpha-2A adrenergic receptor P08913 Details

    References:

    1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. Pubmed
    2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. Pubmed
    3. Newman-Tancredi A, Cussac D, Audinot V, Nicolas JP, De Ceuninck F, Boutin JA, Millan MJ: Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor. J Pharmacol Exp Ther. 2002 Nov;303(2):805-14. Pubmed

    9. 5-hydroxytryptamine receptor 1A

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Actions: agonist

    Components

    Name UniProt ID Details
    5-hydroxytryptamine receptor 1A P08908 Details

    References:

    1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. Pubmed
    2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. Pubmed
    3. Sharif NA, McLaughlin MA, Kelly CR, Katoli P, Drace C, Husain S, Crosson C, Toris C, Zhan GL, Camras C: Cabergoline: Pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in the Cynomolgus monkey eyes. Exp Eye Res. 2009 Mar;88(3):386-97. Epub 2008 Nov 1. Pubmed

    10. Alpha-2C adrenergic receptor

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Actions: antagonist

    Components

    Name UniProt ID Details
    Alpha-2C adrenergic receptor P18825 Details

    References:

    1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. Pubmed
    2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. Pubmed
    3. Newman-Tancredi A, Cussac D, Audinot V, Nicolas JP, De Ceuninck F, Boutin JA, Millan MJ: Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor. J Pharmacol Exp Ther. 2002 Nov;303(2):805-14. Pubmed

    11. D(1B) dopamine receptor

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Actions: agonist

    Components

    Name UniProt ID Details
    D(1B) dopamine receptor P21918 Details

    References:

    1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. Pubmed
    2. Kvernmo T, Hartter S, Burger E: A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther. 2006 Aug;28(8):1065-78. Pubmed
    3. Ichikawa K, Kojima M: [Pharmacological effects of cabergoline against parkinsonism] Nippon Yakurigaku Zasshi. 2001 Jun;117(6):395-400. Pubmed

    12. D(1A) dopamine receptor

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Actions: agonist

    Components

    Name UniProt ID Details
    D(1A) dopamine receptor P21728 Details

    References:

    1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. Pubmed
    2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. Pubmed
    3. Kvernmo T, Hartter S, Burger E: A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. Clin Ther. 2006 Aug;28(8):1065-78. Pubmed
    4. Ichikawa K, Kojima M: [Pharmacological effects of cabergoline against parkinsonism] Nippon Yakurigaku Zasshi. 2001 Jun;117(6):395-400. Pubmed

    13. 5-hydroxytryptamine receptor 1B

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Actions: agonist

    Components

    Name UniProt ID Details
    5-hydroxytryptamine receptor 1B P28222 Details

    References:

    1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. Pubmed
    2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. Pubmed

    14. 5-hydroxytryptamine receptor 2C

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Actions: agonist

    Components

    Name UniProt ID Details
    5-hydroxytryptamine receptor 2C P28335 Details

    References:

    1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. Pubmed
    2. Lam YW: Clinical pharmacology of dopamine agonists. Pharmacotherapy. 2000 Jan;20(1 Pt 2):17S-25S. Pubmed
    3. Sharif NA: Serotonin-2 receptor agonists as novel ocular hypotensive agents and their cellular and molecular mechanisms of action. Curr Drug Targets. 2010 Aug;11(8):978-93. Pubmed
    4. Sharif NA, McLaughlin MA, Kelly CR, Katoli P, Drace C, Husain S, Crosson C, Toris C, Zhan GL, Camras C: Cabergoline: Pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in the Cynomolgus monkey eyes. Exp Eye Res. 2009 Mar;88(3):386-97. Epub 2008 Nov 1. Pubmed

    15. 5-hydroxytryptamine receptor 7

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Actions: antagonist

    Components

    Name UniProt ID Details
    5-hydroxytryptamine receptor 7 P34969 Details

    References:

    1. Sharif NA, McLaughlin MA, Kelly CR, Katoli P, Drace C, Husain S, Crosson C, Toris C, Zhan GL, Camras C: Cabergoline: Pharmacology, ocular hypotensive studies in multiple species, and aqueous humor dynamic modulation in the Cynomolgus monkey eyes. Exp Eye Res. 2009 Mar;88(3):386-97. Epub 2008 Nov 1. Pubmed

    1. Cytochrome P450 3A4

    Kind: protein

    Organism: Human

    Pharmacological action: unknown

    Actions: substrate inhibitor

    Components

    Name UniProt ID Details
    Cytochrome P450 3A4 P08684 Details

    References:

    1. Kvernmo T, Houben J, Sylte I: Receptor-binding and pharmacokinetic properties of dopaminergic agonists. Curr Top Med Chem. 2008;8(12):1049-67. Pubmed

    Comments
    Drug created on June 13, 2005 07:24 / Updated on October 08, 2013 14:22